California
Biotech Insights

Biotech Market Update

Nura Bio raises $74M Series B, Biogen acquires RayThera, Iambic and Bayer AI collaboration

June 23, 2026

Recent Funding: Kopra Bio (SF) raised $9.1M Seed Round to Advance Glioblastoma Virus Therapy UCSF spinout Kopra Bio raised $9.1M (co-led by Andreessen Horowitz and Boutique Venture Partners) to advance KB-516, a replicating retrovirus (RRV) that integrates into brain tumor cells and drives sustained IL-15 immune expression directly within the tumor microenvironment. The company, founded […]

Biotech Leader Spotlight

Subhi Marwari

Founder & CEO of NeuraClick

June 18, 2026

Subhi Marwari is the founder and CEO of NeuraClick, where she invented the company’s AI and click-chemistry platform for engineering next-generation neuropeptide therapeutics for disorders of dysregulated stress circuitry. A well-recognized expert in CNS drug delivery with more than two decades of experience in neuroscience drug development, she has led programs across the full arc of drug development – from discovery through IND-enabling toxicology and into first-in-human – and has advanced five CNS programs to the clinic.

Biotech Market Update

Enliven raises ~$400M, Incyte aquires Vega, Beren secures $300M

June 16, 2026

Recent Funding: SonoThera (SF) Closes $125M Series B for Ultrasound-Mediated Genetic Medicines SonoThera (SSF) Closes $125M Series B for Ultrasound-Mediated Genetic Medicines • SonoThera, which uses its RIPPLE™ ultrasound delivery and PORE™ payload engineering to deliver DNA, RNA, and gene-editing payloads non-virally, closed an oversubscribed $125M Series B on June 10. The round was led […]

Biotech Leader Spotlight

Alan Cohen

CMO at Arcturus Therapeutics

June 11, 2026

Alan H. Cohen, MD is the Chief Medical Officer at Arcturus Therapeutics. He is a board-certified Pediatric Pulmonologist with a longstanding interest in cardio-respiratory illnesses. He has been clinically active for the balance of his 35+ years of practice, with a focus on caring for people with Cystic Fibrosis, as well as previously co-directing the largest and most active pediatric lung transplantation program in North America. In addition to his many years of clinical practice, biomedical and basic science research, and teaching, he has dedicated over 25 of his 35+ year-long professional career to drug discovery, in the Biotech & Pharma clinical/medical research space, at both small, entrepreneurial pre-IPO start-ups, as well as more well-established public companies worldwide. He has most recently worked in the fields of heart failure (amyloid-related) and pulmonary hypertension, respiratory infectious diseases (P. aeruginosa, influenza and RSV), as well as gene editing/gene therapy targeting monogenetically driven conditions, including rare and more common diseases such as alpha-1 antitrypsin deficiency, amyloidosis, cystic fibrosis, hemophilia and Fabry Disease.

Biotech Market Update

NewLimit raises $435M Series C, Nurix inks $2.3B deal with Roche, J&J acquires Firefly Bio

June 9, 2026

Recent Funding: NewLimit (SF) Raises $435M Series C to Take Age-Reprogramming Drug to Human Trials Longevity biotech NewLimit closed a $435M Series C led by Founders Fund with participation from Thrive Capital, Kleiner Perkins, Eli Lilly Ventures, and others, pushing its valuation to $3.1B — more than three times where it stood twelve months ago. […]

Biotech Market Update

Protuoso raises $9.5M Seed, Gilead cuts 51 roles, Vaccine Company acquired by Lilly

June 2, 2026

Recent Funding: Protuoso Biosciences (SF) Raises $9.5M Seed to Advance MUXBODY Biologics Platform The oversubscribed seed round — led by Taya Venture and Darwin Ventures with NSG Ventures, SEEDS, and others — will fund Protuoso’s modular MUXBODY fusion-protein platform, designed to engineer multi-specific biologics for cardiometabolic, oncology, and autoimmune indications. The company operates a therapeutic-agnostic […]

California Biotech Insights

California
Biotech Insights